Welcome to our dedicated page for AMERISOURCEBERGEN news (Ticker: abc), a resource for investors and traders seeking the latest updates and insights on AMERISOURCEBERGEN stock.
Cencora, Inc. (NYSE: COR) is a global pharmaceutical solutions leader driving innovation across healthcare supply chains. This page provides investors and industry professionals with essential updates on Cencora's strategic initiatives, financial developments, and operational milestones.
Access real-time press releases and analysis covering Cencora's pharmaceutical services, including distribution network expansions, biopharma partnerships, and regulatory advancements. Track key developments such as acquisitions in specialty healthcare, global commercialization efforts, and social responsibility programs through the Cencora Impact Foundation.
Stay informed about critical updates including earnings reports, supply chain innovations, and strategic investments like the OneOncology and PharmaLex acquisitions. Our curated news collection ensures you never miss developments impacting Cencora's position as a Fortune 500 healthcare leader operating in 50+ countries.
Bookmark this page for streamlined access to verified updates about Cencora's pharmaceutical distribution services, venture capital activities through Cencora Ventures, and initiatives advancing global healthcare access. Check regularly for authoritative insights into this NYSE-listed industry pioneer.
AmerisourceBergen Corporation (NYSE: ABC) reported a 13.5% increase in revenue for Q1 2022, totaling $59.6 billion, compared to the same quarter last year. The company achieved a GAAP diluted EPS of $2.13, rising from $1.81 in the prior year quarter. Adjusted diluted EPS was $2.58, reflecting an 18.3% growth year-over-year. AmerisourceBergen also raised its adjusted diluted EPS guidance for fiscal 2022 to a range of $10.60 to $10.90.
AmerisourceBergen Corporation (NYSE: ABC) will announce its First Quarter Fiscal 2022 results on February 2, 2022, prior to NYSE trading. A conference call, featuring CEO Steven H. Collis and CFO James F. Cleary, will commence at 8:30 a.m. ET the same day. Investors can access the call via telephone or through a live webcast on the company’s website. The webcast will also be available for replay. AmerisourceBergen ranks #8 on the Fortune 500, with over $200 billion in annual revenue.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have extended the deadline for political subdivisions to join the proposed opioid settlement from January 2, 2022, to January 26, 2022. New Mexico confirmed its participation, raising total states in the settlement to 43, covering all U.S. territories and Washington, D.C. The deadline to assess sufficient participation has also been moved from February 1, 2022, to February 25, 2022. The companies aim to expedite relief to affected communities and remain committed to addressing the opioid crisis.
AmerisourceBergen reported a 19.6% revenue increase for Q4 FY2021, totaling $58.9 billion, and a 12.7% rise for the fiscal year, reaching $214.0 billion. GAAP diluted EPS for Q4 was $2.08, significantly improved from last year's loss of $(23.74). Adjusted diluted EPS rose 26.5% to $2.39. Gross profit in Q4 surged 53.6% to $2.1 billion, aided by the Alliance Healthcare acquisition. Operating income was $562 million, reflecting a recovery from last year's loss.
AmerisourceBergen Corporation (NYSE: ABC) is set to announce its Fourth Quarter Fiscal 2021 results on November 4, 2021, before market opening. A conference call will follow at 8:30 a.m. ET on the same day, featuring CEO Steven H. Collis and CFO James F. Cleary. Investors can join the call via phone or webcast, accessible on the company’s investor relations website.
With over $200 billion in annual revenue, AmerisourceBergen ranks #8 on the Fortune 500, highlighting its significant presence in global healthcare.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Cherokee Nation for approximately $75 million over 6.5 years. This agreement resolves ongoing litigation and allows the companies to focus on safe medication delivery. The settlement is part of broader negotiations with federally recognized Native American tribes, despite the companies disputing the allegations against them. The firms emphasize their commitment to addressing the opioid epidemic's impact on communities.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) announced progress on the opioid claims settlement involving U.S. states and territories. As of August 21, 2021, 42 states, 5 territories, and Washington, D.C. have joined the settlement, allowing the process to move forward. This next phase includes a 120-day period for political subdivisions to join, ending January 2, 2022. If enough subdivisions participate, the settlement will take effect 60 days after that. The companies aim to focus on secure medication delivery while providing relief to affected communities.
AmerisourceBergen Corporation (NYSE: ABC) announced its virtual participation in two upcoming investor conferences. The conferences include the Morgan Stanley 19th Annual Global Healthcare Conference, scheduled for September 9-10 and September 13-15, 2021, and the Baird 2021 Global Healthcare Conference on September 14-15, 2021. Investors can find updates and potential webcast information on the investor relations website.
AmerisourceBergen Corporation (NYSE: ABC) reported a 17.7% year-over-year increase in revenue for Q3 fiscal 2021, reaching $53.4 billion. Diluted earnings per share (EPS) were $1.40, slightly down from $1.41 in the previous year. However, adjusted diluted EPS rose 16.8% to $2.16, reflecting strong performance. The company also updated its financial outlook for fiscal year 2021, indicating potential growth.
